Thursday, March 5, 2015
AbbVie Wins Bidding War for Maker of Cancer Drug, Then Goes on Defensive by ANDREW POLLACK
By ANDREW POLLACK
Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much.
Published: March 6, 2015 at 01:00PM
from NYT Business Day http://ift.tt/1aOPSns
via IFTTT
Read more...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment